Omnipaque 300 mgi ml

The population pharmacokinetic model and associated LSS for iohexol serum clearance have previously been described in detail [9 (link)]. In short, a non-parametric adaptive grid (NPAG) approach implemented in Pmetrics [11 (link)] for R [12 ] was used. The model consisted of two compartments, parameterized in clearance (CL) from the central compartment, the volume of central (V) and peripheral (Vp) compartments, and inter-compartmental blood flow (Q), allometrically scaled for body weight using power factors of 0.75 for CL and Q and 1 for V and Vp. The model was developed on rich data from 176 patients (1131 samples), and externally validated in a cohort of 43 patients (395 samples). The 4-point sampling strategy optimized for clinical use included samples at 10 min, 30 min, 2 h, and 5 h following intravenous administration of 3235 mg iohexol (Omnipaque 300 mg I/mL, GE Healthcare AS, Oslo, Norway). A public, web-based interface to this model was developed and is freely available at https://www.mgfr.no.

A radiographic examination was carried out using a digital radiography system (Leonardo DR System). Radiographic imaging of the thorax, spine, and tympanic bullae was carried out in accordance with the standardized protocols. Radiographs were analyzed using a DICOM PACS DXR X-Ray (CareRay Version: 6.0.61-186) Acquisition Software workstation.
The abdominal ultrasound was carried out using a mikrokonvex 3–9 MHz probe and a linear 10–12 MHz probe (EsaoteMyLab Twice). During the examination, the animals were laid in dorsal recumbency.
All animals were sedated for the tomography examination with inhalation anesthesia (isoflurane), and laid in sternal recumbency. Tomography was performed using a Philips MX-16 slice unit CT scanner at a 120 kV tube voltage and 120 mA, with a slice thickness of 1 mm. The postcontrast examination was carried out following the intravenous administration of the contrast agent at a dose of 600 mgI/kg iohexol (Omnipaque 300 mgI/mL; GE Healthcare, Oslo, Norway). The raw data were reconstructed in soft tissue (window level, 40 HU; window width 350 HU), brain (window level, 40 HU; window width, 120 HU), and bone (window level, 500 HU; window width, 1600 HU) algorithms. Tomographic images were reviewed and analyzed on a DICOM PACS Acquisition Software workstation (Philips IntelliSpace Portal, Philips Medical Systems Nederland B.V., Bests, The Netherlands).

Given the duration of the period of investigation, different CT scanners and protocols were used. Our current CTA protocol is performed with a 128- or 384-detector row scanner (Somatom Definition or Force, Siemens, Erlangen, Germany) with a scan range from the apex of the lung to its base.
Approximately 80 to 100 mL of contrast agent (Omnipaque 300 mgI/mL; GE Healthcare, Oslo, Norway) is injected at 4 mL/s through the antecubital vein, followed by 30 mL (2 mL/s) of saline solution.
Automatic bolus-triggering software is used, with a circular region of interest positioned at the level of the pulmonary trunk for pulmonary artery evaluation and at the level of the descending aorta for systemic artery evaluation. Post-processing is performed on conventional dedicated software.